Key Highlights

● Abbott will report third-quarter results on 21 October 2026 before the US market opens.

● Second-quarter net sales were $12,593 million, up 13.0% reported and 4.8% comparable.

● GAAP diluted EPS was $0.53 against $1.01, while adjusted EPS was $1.31.

● Cancer Diagnostics contributed $919 million, with 13.3% comparable growth.

Abbott Laboratories (NYSE:ABT), the diversified healthcare company, will report third-quarter 2026 results on Wednesday 21 October 2026 before the US market opens. A company announcement dated 30 September 2026 said that a live webcast will begin at 9:00 a.m. Eastern time (8:00 a.m. Central) through its investor relations website, with a replay posted later the same day.

The most recent reported quarter

The last reported period is the second quarter, released on 16 July 2026. Net sales were $12,593 million, up 13.0% on a reported basis and 4.8% on a comparable basis. Diluted earnings per share were $0.53 under US generally accepted accounting principles, against $1.01 a year earlier, while adjusted diluted earnings per share were $1.31, compared with $1.26, an increase of 4.0%.

By segment, Medical Devices sales were $5,853 million, up 9.0% reported and 8.4% comparable. Diagnostics reached $3,092 million, up 42.3% reported but only 2.9% comparable. Established Pharmaceuticals recorded $1,499 million, up 8.4% reported and 8.7% comparable. Nutrition was the weak spot at $2,144 million, down 3.1% reported and 3.6% comparable.

The Exact Sciences effect

The gap between reported and comparable growth, particularly in Diagnostics, reflects Abbott's acquisition of Exact Sciences, which the company said it completed on 23 March 2026. Cancer Diagnostics sales were $919 million in the second quarter, with comparable growth of 13.3%, and Abbott said Cologuard grew in the mid-teens. Exact Sciences' worldwide sales for 2025 were $3.247 billion, which gives a sense of the scale added. Management included Exact Sciences' sales in comparable growth for both periods.

The sharp difference between the GAAP and adjusted earnings figures suggests acquisition-related and other items weighed on the GAAP result.

Management guidance

These are company expectations, not analyst forecasts. For the third quarter of 2026, Abbott guided to adjusted diluted earnings per share of $1.38 to $1.46. For the full year 2026, it raised its adjusted earnings per share range to $5.45 to $5.60 from $5.38 to $5.58, and it reaffirmed comparable sales growth of 6.5% to 7.5%.

The raise lifted the bottom of the range by $0.07 and the top by $0.02, narrowing it. The third-quarter range sits above the $1.31 adjusted figure for the second quarter, so management appears to expect sequential improvement. The raise also leaves comparable sales guidance unchanged, which suggests the change came from earnings rather than revenue expectations.

Why the date matters

The third-quarter release is the first scheduled opportunity to see how the guided range compares with the actual outcome, and to see whether the integration of Exact Sciences, the performance of devices and the pressure in nutrition continue. Investors and analysts will also watch whether the full-year range is changed again.

Limitations

Amounts are US dollars and refer to the quarter ended 30 June 2026 unless stated. Reported and comparable growth rates use different bases, so they should not be compared directly.

The 21 October Webcast Will Show How Results Compare With Guidance

The next dated event is the earnings release and webcast on 21 October 2026, with an archived replay on Abbott's investor relations site.